Showing results (121-130 of 279) with videos related to
Sort By:
Pageof 28
Anti-Cancer Drugs|November 29, 2007
A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumorsD Ross Camidge, S Gail Eckhardt, Lia Gore, et al.Cancer Discovery|July 31, 2014
Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutationsYelena Y Janjigian, Egbert F Smit, Harry J M Groen, et al.Cancer Research Communications|July 21, 2026
Targeting Wild-type NTRK in NTRK Fusion-Negative Lung Cancer Decreases Brain MetastasesMaria J Contreras-Zárate, Jenny A Jaramillo-Gómez, R Alejandro Marquez-Ortiz, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 18, 2020
Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX StudyTony Mok, Solange Peters, D Ross Camidge, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 2, 2019
Natural History and Factors Associated with Overall Survival in Stage IV ALK-Rearranged Non-Small Cell Lung CancerJose M Pacheco, Dexiang Gao, Derek Smith, et al.Investigational New Drugs|March 12, 2017
Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancersJennifer R Diamond, Barbara Goff, Martin D Forster, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 10, 2021
Outcomes According to ALK Status Determined by Central IHC or FISH in Patients with ALK-Positive NSCLC Enrolled in the Phase III ALEX StudyTony Mok, Solange Peters, D Ross Camidge, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2022
Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non-small Cell Lung Cancer in the Global Phase III ALEX TrialRafal Dziadziuszko, Solange Peters, Tony Mok, et al.Biorxiv : the Preprint Server for Biology|March 27, 2026
Targeting wild type NTRK decreases brain metastases of lung cancers non-driven by NTRK fusionsMaria J Contreras-Zárate, Jenny A Jaramillo-Gómez, R Alejandro Marquez-Ortiz, et al.Future Oncology (London, England)|November 29, 2019
Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancerJeffrey W Clark, D Ross Camidge, Eunice L Kwak, et al.Pageof 28